Compare Heron Therapeutics Inc (HRTX) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Omnicom Group Inc. — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Omnicom Group Inc. trades at $76.35 (market cap $20.54B). The key difference: Omnicom Group Inc. is far larger — about 277.4× Heron Therapeutics Inc's market cap, and Omnicom Group Inc. pays a 4.27% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Omnicom Group Inc. for 63 Days on average.
| HRTX | OMC | |
|---|---|---|
Market Cap | $74.04M | $20.54B |
Volume | 3,668,095 | 1,803,209 |
Sector | Health | Media |
52-Week High | $1.49 | $88.94 |
52-Week Low | $0.27 | $67.27 |
Typical Hold Time | 35 Days | 63 Days |
Enterprise Value | $180.78M | $28.62B |
Dividend Yield | — | 4.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
OMC trades at $76.45, up 1.8% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $54.5 million in 2025 despite revenue growth to $17.27 billion, though 2026 projections show a return to profitability. Recent news highlights leadership in digital marketing and significant new business wins, including $3.3 billion in H1 2026 billings.
The stock presents a value opportunity with a low P/S of 0.84 and a consensus price target of $104.67, implying 37% upside. However, high P/E of 202.35, recent net loss, and advertising market volatility pose risks. Analyst sentiment is cautious with 59% hold ratings, reflecting balanced near-term prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
